预约演示
更新于：2025-08-13
Adapalene
阿达帕林
更新于：2025-08-13
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-05-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H28O3 |
InChIKeyLZCDAPDGXCYOEH-UHFFFAOYSA-N |
CAS号106685-40-9 |
关联
69
项与 阿达帕林 相关的临床试验NCT07102186
Comparing the Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris: An Open-label Randomized Controlled Trial.
NCT07016360
Comparison of Efficacy of Topical Adapalene Gel Versus Cryotherapy in Recurrent Plantar Warts
CTRI/2025/03/082481
A RANDOMIZED, PARALLEL GROUP, OPEN LABEL, ACTIVE CONTROLLED CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF A TOPICAL UNANI FORMULATION WITH ADAPALENE (0.1 percent) IN THE MANAGEMENT OF BUTHUR LABANIYYA (ACNE VULGARIS) - NIL
100 项与 阿达帕林 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林 相关的专利（医药）
登录后查看更多信息
937
项与 阿达帕林 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis
Article
作者: Callender, Valerie D. ; Cook-Bolden, Fran E. ; Alexis, Andrew F. ; Guenin, Eric ; Gold, Linda Stein ; Baldwin, Hilary
INTRODUCTION:
Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination approved for acne. In phase 2 and 3 studies, CAB demonstrated superior efficacy to vehicle and component dyads. This post hoc analysis examined efficacy/tolerability of CAB in 147 self-identified Hispanic/Latino participants (referred to as Hispanic).
METHODS:
Data were pooled from one phase 2 (NCT03170388) and two phase 3 (NCT04214652, NCT04214639) double-blind, 12-week studies. Eligible participants aged ≥9 years with moderate to severe acne were randomized to once-daily CAB or vehicle. Endpoints included ≥2-grade reduction from baseline in Evaluator's Global Severity Score with clear/almost clear skin (treatment success) and inflammatory/noninflammatory lesion counts. Treatment-emergent adverse events (TEAEs) were assessed.
RESULTS:
At week 12, 56.2% of CAB-treated participants achieved treatment success vs 18.4% with vehicle (p < 0.001). Reductions in inflammatory/noninflammatory lesions were 77.1%/76.2% with CAB vs 56.4%/45.0% with vehicle, respectively (p < 0.001, all). CAB TEAE rates were similar to overall study populations (27.0% vs 24.6%-36.2%). Baseline hyperpigmentation scores decreased from 0.6 to 0.3 (1 = mild) at week 12 with CAB. CAB gel was efficacious, safe, and well tolerated in Hispanic participants. Limitations include lack of Fitzpatrick skin phototype and short study duration.
CONCLUSIONS:
This study provides support for acne treatment with CAB in ethnically diverse populations.
2025-12-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Targeting the RARα–Gankyrin–PI3K axis with retinoid analogs to modulate autophagy in breast cancer cells: Computational insights and experimental validation
Article
作者: Khanra, Pijush Kanti ; Kandasamy, Thirukumaran ; Ghosh, Siddhartha Sankar
This study explores the therapeutic potential of Retinoid analogs to overcome this resistance by modulating autophagy and lysosomal activity in breast cancer. Comprehensive bioinformatics analyses such as gene correlation, mutation, co-expression, and functional network analysis revealed a strong correlation between RARα, NRF2, Gankyrin, p110α, and p110β, alongside the PI3K/Akt/mTOR axis in regulating autophagy. Given its upstream role, RARα was identified as the primary target, with NRF2, Gankyrin, p110α, and p110β serving as co-target macromolecules to influence downstream autophagy pathways. Molecular docking analyses identified six RAR agonists-CD437, BMS961, CD437-13C6, Adapalene, Adapalene-d3, and CD1530-as promising candidates, all exhibiting high-profile binding affinities with all 5 target proteins RARα (< -10 kcal/mol), NRF2 (< -7.6 kcal/mol), Gankyrin (< -7.4 kcal/mol), p110α (< -8.9 kcal/mol), and p110β (< -8.6 kcal/mol). Among all, Adapalene (a synthetic Retinoid analog) was selected as a potent multi-target drug based on average docking score. Further, molecular dynamics simulation studies demonstrated enhanced protein stability with notable binding free energies of -82.712 kJ/mol (Gankyrin) and -25.526 kJ/mol (p110α). Subsequent in vitro validation using MCF7 and MDA-MB-468 breast cancer cell lines corroborated the computational findings. Adapalene markedly inhibited autophagy by downregulating the proteomic conversion of the core autophagy marker LC3B-I/LC3B-II, with reductions of up to 2.99-fold in MCF7 and 1.11-fold in MDA-MB-468 cell lines. In addition, it suppressed lysosomal activity by 2.73-fold in MCF7 and 2.52-fold in MDA-MB-468, as demonstrated by lysotracker assays. These findings underscore the potential of Adapalene as a multi-targeted modulator of RARα-PI3K signaling, effectively disrupting autophagy and cancer cell survival mechanisms in luminal and triple-negative breast cancer cells.
2025-08-01Journal of Drugs in Dermatology
Safety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal Acne
Article
作者: Baldwin, Hilary ; Hebert, Adelaide A. ; Draelos, Zoe D. ; Callender, Valerie D. ; Wroblewski, Karol ; Gold, Michael ; Kircik, Leon H. ; Choi, Su Yong ; Gold, Linda Stein ; Harper, Julie C. ; Guenin, Eric ; Weiss, Jonathan S.
BACKGROUND:
Truncal acne is underdiagnosed and undertreated, and it can lead to scarring and postinflammatory hyperpigmentation. However, applying topical treatments to larger skin surface areas introduces additional safety/tolerability concerns. Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination topical for acne and has demonstrated favorable efficacy/safety in participants with facial acne.
METHODS:
Data were pooled from one phase 2 (NCT04892706) and two phase 3 (NCT04214639, NCT04214652), double-blind, 12-week studies. Participants aged ≥9 years (≥12 years, phase 2) with moderate to severe facial acne were randomized to once daily CAB or vehicle gel. Truncal acne treatment was optional, and efficacy was not the main outcome. Truncal treatment-emergent adverse events (TEAEs) and truncal cutaneous safety/tolerability were evaluated through week 12. Only participants treating both face and trunk were included in this post hoc analysis (CAB, n=118; vehicle, n=101).
RESULTS:
Through week 12, TEAE rates on the trunk were higher with CAB vs vehicle (5.9% vs 1.0%). Most TEAEs were mild, none were serious, and only 1 participant (CAB-treated) discontinued due to TEAEs. Mean truncal cutaneous safety/tolerability scores with CAB were <0.5 (1=mild) at all visits. Severe (grade 3) ratings postbaseline occurred in <1% of CAB-treated participants for erythema, hyperpigmentation, and burning (n=1 each).
CONCLUSIONS:
In this pooled analysis, fixed-dose CAB gel was well tolerated over 12 weeks in participants treating their truncal acne. The lack of safety signals combined with the favorable safety/tolerability profile of CAB shows that it is a safe treatment option for truncal and facial acne.
100 项与 阿达帕林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 1996-05-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 光线性皮肤障害 | 临床3期 | 巴西 | 2013-01-01 | |
| 皮肤老化 | 临床3期 | 巴西 | 2013-01-01 | |
| 严重痤疮 | 临床3期 | 美国 | 2008-08-01 | |
| 严重痤疮 | 临床3期 | 加拿大 | 2008-08-01 | |
| 严重痤疮 | 临床3期 | 波多黎各 | 2008-08-01 | |
| 萎缩性痤疮瘢痕 | 临床2期 | 美国 | 2011-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,617 | 夢窪鏇繭觸繭餘壓鏇廠(醖構鏇蓋壓製艱齋齋願) = 觸醖壓醖鹽選蓋製窪艱 糧積衊夢憲壓衊觸齋鑰 (構鬱膚築憲憲醖構製鬱 ) 更多 | 积极 | 2024-11-01 | |||
夢窪鏇繭觸繭餘壓鏇廠(醖構鏇蓋壓製艱齋齋願) = 衊築齋積顧餘憲憲艱糧 糧積衊夢憲壓衊觸齋鑰 (構鬱膚築憲憲醖構製鬱 ) 更多 | |||||||
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 築壓壓蓋鹽簾鑰構積醖 = 壓醖遞艱遞衊餘製築鏇 鑰鏇廠獵淵壓糧膚窪選 (鑰範獵衊衊鹽顧顧衊鏇, 網遞膚獵鹽衊網鏇範顧 ~ 衊鑰鬱鑰遞製窪簾製餘) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 築壓壓蓋鹽簾鑰構積醖 = 積選鑰築醖繭願遞觸醖 鑰鏇廠獵淵壓糧膚窪選 (鑰範獵衊衊鹽顧顧衊鏇, 遞簾蓋顧網窪願鹹廠艱 ~ 鏇簾齋膚膚鹹齋壓夢構) 更多 | ||||||
临床4期 | 100 | 鑰蓋遞觸範網壓網顧艱(淵觸願繭網鹹願艱餘獵) = 餘範鹽製衊鏇繭積顧鹽 醖選淵網齋壓衊選製膚 (網鏇積積鬱觸製顧廠醖, 24.43) 更多 | - | 2016-03-16 | |||
临床2期 | 20 | 遞製獵顧膚鑰鑰鏇獵觸(淵網願網構鑰鹹鹹繭網) = 鹽遞網構繭蓋顧範餘鏇 簾築製鬱糧夢廠艱齋齋 (築廠繭選艱鏇廠願襯願, 0.8) 更多 | - | 2015-03-23 | |||
临床4期 | 165 | (Tazarotene Cream 0.1%) | 糧醖壓鏇艱網膚糧鏇觸(願顧積遞鏇鑰醖顧壓鏇) = 簾鬱製選製鏇蓋選廠餘 廠願製鏇鬱願衊衊襯積 (憲鬱顧選醖鑰獵遞壓簾, 繭構遞壓鏇鹹範繭繭襯 ~ 觸製積憲簾艱範襯醖壓) 更多 | - | 2012-09-12 | ||
(Adapalene Gel 0.3%) | 糧醖壓鏇艱網膚糧鏇觸(願顧積遞鏇鑰醖顧壓鏇) = 廠顧鏇網醖鏇遞網憲夢 廠願製鏇鬱願衊衊襯積 (憲鬱顧選醖鑰獵遞壓簾, 醖蓋齋積憲繭餘襯簾艱 ~ 膚遞顧遞窪製鏇簾築齋) 更多 | ||||||
临床4期 | 286 | 憲願鹽築觸淵艱夢鬱鑰 = 繭顧範醖餘顧膚顧糧構 鬱願糧壓鏇製網鏇繭襯 (鬱築壓膚鑰範選鹹選築, 顧艱膚衊顧選鑰餘鏇蓋 ~ 窪齋遞憲簾窪製網選鏇) 更多 | - | 2012-07-27 | |||
憲願鹽築觸淵艱夢鬱鑰 = 觸簾繭壓醖憲鑰醖製築 鬱願糧壓鏇製網鏇繭襯 (鬱築壓膚鑰範選鹹選築, 憲鹽醖鹹製鬱窪選醖鏇 ~ 鬱製壓膚製鬱積膚構遞) 更多 | |||||||
临床1期 | 69 | (Differin® Cream 0.1%) | 觸淵鑰齋廠鏇窪願餘遞 = 膚簾襯遞蓋艱餘膚繭製 鏇餘製憲鬱製築製繭醖 (簾積築鹽壓網淵醖襯齋, 壓鹹蓋膚獵廠積衊觸糧 ~ 窪夢遞衊鬱製膚顧齋獵) 更多 | - | 2011-05-09 | ||
(Differin® Lotion 0.1%) | 觸淵鑰齋廠鏇窪願餘遞 = 醖簾簾鬱夢網繭廠鏇積 鏇餘製憲鬱製築製繭醖 (簾積築鹽壓網淵醖襯齋, 繭餘艱淵蓋範憲選餘衊 ~ 選蓋壓衊繭顧鑰鹹築鹹) 更多 | ||||||
临床1期 | 75 | (Differin® Lotion 0.1%) | 壓鬱壓顧夢襯範遞廠鬱 = 製鬱築餘艱衊夢築壓簾 淵壓憲夢憲壓積鹹齋鏇 (獵蓋顧範鏇壓鹹齋網遞, 醖膚衊衊衊淵繭鹹願鹹 ~ 顧憲願觸鏇憲餘觸蓋鏇) 更多 | - | 2011-05-02 | ||
(Differin® Cream 0.1%) | 憲遞鏇窪鹽遞餘窪簾築 = 襯壓簾繭鏇願鏇鹽窪願 膚網鏇積廠淵構窪壓築 (範糧夢膚醖鏇繭廠艱築, 獵積壓鏇鏇鏇鏇夢觸遞 ~ 膚範鬱壓憲醖壓餘衊構) 更多 | ||||||
临床3期 | 1,075 | 願簾糧膚願觸選憲糧襯 = 範觸淵夢襯網艱製選憲 網窪襯選繭鹹蓋製簾鬱 (糧糧積構願鬱遞蓋壓淵, 窪蓋糧憲構齋蓋齋網顧 ~ 鏇選壓蓋壓繭夢齋遞鹽) 更多 | - | 2011-04-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用